The drug pricing regulator has directed manufacturers to regularly furnish production and sales data for scheduled formulations to strengthen monitoring of essential medicines
NPPA raises ceiling prices of key cancer drugs and select vaccines to address supply shortages and ensure continued availability of essential medicines
Drug pricing regulator permits marginal MRP increase for NLEM medicines in line with wholesale price index, offering relief to manufacturers facing higher costs
The NPPA has extended the knee implant price cap despite industry requests to remove or relax it, citing rising costs and innovation needs, as the regulator prioritises affordability for patients
The NPPA has extended the ceiling price for knee implants till November 2025 while considering industry pleas for removal, citing rising costs and supply chain issues
The NPPA has capped prices for 41 drug combinations including diabetes, cholesterol, and sleep disorder treatments, citing steep price drops and growing generic availability
The NPPA has fixed retail prices for 84 drug formulations, including 36 combinations of off-patent diabetes drug empagliflozin, after a steep drop in prices
With the changes, manufacturers will be allowed to increase the maximum retail price (MRP) of scheduled formulations on the basis of WPI without needing any prior approval from the government
With this, manufacturers will be allowed to increase the maximum retail price (MRP) of scheduled formulations on the basis of WPI without needing any prior approval from the government in this regard
Under the AMRIT initiative, medicines for cancer, cardiovascular diseases, and surgical implants are available at up to 50 per cent discounts in selected hospital pharmacies
The regulatory body, which comes under the Department of Pharmaceuticals (DoP), took the decision to revise the prices of the formulations during the authority's 130th meeting on February 25
The National Pharmaceutical Pricing Authority directs pharma firms to revise the MRP of medicines following customs duty exemptions in Union Budget 2025, ensuring consumers benefit from lower prices
Parliamentary panel slams drug pricing regulator for hike on 11 drugs used for treating conditions such as asthma, glaucoma, thalassemia, tuberculosis, and mental health disorders
The ceiling prices of seven other drugs were revised to include the impact of the 0.00551 per cent increase in drug prices in the National List of Essential Medicines
Ceiling prices were also revised for the asthma drug Salbutamol in tablets of 2 mg and 4 mg formulations and respirator solution of 5 mg/ml formulation
Prices of essential drugs such as dapagliflozin metformin hydrochloride, used for lowering blood glucose levels by decreasing glucose production in the liver, have been fixed at Rs 16 per tablet
The formulations in the new revised rate list include essential drugs such as painkillers, antivirals, antibiotics, antimalarials, and drugs for type 2 diabetes
